Skip to Main Content

Paper Details

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer.
Cell Rep
21
2021
ERs, HRLPC, High-risk localized prostate cancer, NRs, PTEN, SPOP, SPOPL, TGF, TP53, androgen, androgens, high-risk localized prostate cancer, patient, tumor
Author NameAffiliation
Alok K TewariDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Jake ConwayDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Stephanie A WankowiczDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Dimitri LivitzBroad Institute of MIT and Harvard
Jihye ParkDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Jihye ParkDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Rosina T LisDana-Farber Cancer Institute
Ignaty LeshchinerBroad Institute of MIT and Harvard
Myles BrownDana-Farber Cancer Institute
Gad GetzBroad Institute of MIT and Harvard, Massachusetts General Hospital
Gad GetzBroad Institute of MIT and Harvard, Massachusetts General Hospital
Mary-Ellen TaplinDana-Farber Cancer Institute
Eliezer M Van AllenDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
Eliezer M Van AllenDana-Farber Cancer Institute, USA Broad Institute of MIT and Harvard
  • 1 - 14

Datasets